公开(公告)号：US20240167021A1

公开(公告)日：2024-05-23

申请号：US18430589

申请日：2024-02-01

申请人： ACADEMY OF MILITARY MEDICAL SCIENCES, ACADEMY OF MILITARY SCIENCES OF CHINESE PLA ,  BEIJING JIUYU ONCOLGY CO., LTD.

发明人： Zhiqiang LIU ,  Zengqiang YUAN ,  Cui WANG ,  Xiaowen XING ,  Bingshui XIU ,  Shihong LIU

IPC分类号： C12N15/10 ,  C12N15/65 ,  C12N15/86

CPC分类号： C12N15/1086 ,  C12N15/65 ,  C12N15/86 ,  C12N2740/15022 ,  C12N2740/15043

摘要： A fusion imaging gene and lentiviral expression plasmid, lentivirus and cell, and preparation methods and applications thereof are provided. The fusion imaging gene includes bioluminescence imaging gene, fluorescent protein gene and calcium imaging gene. The three genes are linked by linkers. The fusion gene is inserted into a modified lentiviral expression plasmid to obtain lentivirus particles carrying the fusion imaging gene.

公开(公告)号：US20180258142A1

公开(公告)日：2018-09-13

申请号：US15917761

申请日：2018-03-11

申请人： Cherry Med, Inc.

发明人： David I. Cohen

IPC分类号： C07K14/005 ,  C07K16/28 ,  C07K16/22 ,  C07K16/46 ,  A61P35/00 ,  A61P35/04 ,  C07K14/715 ,  C07K14/82

CPC分类号： C07K14/005 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/04 ,  C07K14/7151 ,  C07K14/82 ,  C07K16/00 ,  C07K16/22 ,  C07K16/2878 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/50 ,  C12N2740/15022 ,  C12N2740/15033 ,  C12N2740/16022 ,  C12N2740/16033 ,  C12N2740/16322

摘要： The present invention describes unique means for reducing autoreactivity that sensitizes against sustained treatments, and toxicity associated with administration of biologicals, in order to develop safer cancer immunotherapeutics. Short functional sequences are identified in the biologic and matched to their most homologous human counterpart. The human homologs are swapped in to replace their foreign counterparts. Alternatively, variants are selected that have exhibit less toxicity in human or primate experiments from nature, and these sequences are swapped in to replace their counterparts in the biologic. Also, human sequences that mediate the same function as foreign sequences in the biologic, but lack any sequence homology, can be swapped in for their foreign sequence counterparts. These inventions are applied to derivatize the HIV/SIV Tat protein into humanized trimers (CATS) useful for the treatment of cancer.

公开(公告)号：US09974852B2

公开(公告)日：2018-05-22

申请号：US14896505

申请日：2014-06-06

申请人： VIROXIS S.A.S. ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT GUSTAVE ROUSSY ,  UNIVERSITE PARIS-SUD XI

发明人： Thierry Heidmann

IPC分类号： A61K48/00 ,  A61K39/00 ,  C12N15/00 ,  C12N15/63 ,  A61K39/21 ,  A61K39/12 ,  C07K14/005

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/572 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/15034

摘要： A pharmaceutical composition includes, as active substance a mutated non-primate lentiviral Env protein having decreased immunosuppressive properties, substantially no immunosuppressive properties or no immunosuppressive properties, or a variant of the mutated lentiviral Env protein, or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

公开(公告)号：US09962436B2

公开(公告)日：2018-05-08

申请号：US14416780

申请日：2013-07-26

申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

发明人： James J Mond ,  Clifford M. Snapper ,  Xinle Cui

IPC分类号： A61K39/245 ,  C07K14/005 ,  A61K39/21 ,  A61K39/12 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/57 ,  A61K2039/70 ,  C07K14/005 ,  C07K2319/00 ,  C12N2710/16234 ,  C12N2740/15022 ,  C12N2740/15034 ,  Y02A50/386 ,  Y02A50/403 ,  Y02A50/478

摘要： The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizmg antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins, Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.

公开(公告)号：US20180099041A1

公开(公告)日：2018-04-12

申请号：US15694388

申请日：2017-09-01

申请人： The Regents of the University of California

发明人： Phillip Berman ,  Sara O'Rourke ,  William Scott

IPC分类号： A61K39/21 ,  A61K39/12 ,  G01N33/569 ,  A61K38/16 ,  C07K14/005

CPC分类号： A61K39/21 ,  A61K38/162 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2500/02

摘要： Selection of HIV vaccine antigens by use of intrapatient sequence variation to identify mutations in the HIV envelope glycoprotein that affect the binding of broadly neutralizing antibodies and polypeptides identified by these methods.

公开(公告)号：US09913895B2

公开(公告)日：2018-03-13

申请号：US14617711

申请日：2015-02-09

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

发明人： Janet K. Yamamoto

IPC分类号： A61K39/21 ,  A61K45/06 ,  C07K14/005 ,  C07K16/10 ,  C12N7/00 ,  G01N33/569 ,  A61K39/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/552 ,  A61K2039/57 ,  C07K14/005 ,  C07K16/1045 ,  C07K16/1054 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C12N7/00 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/16034 ,  C12N2740/16222 ,  C12N2740/16234 ,  G01N33/56983 ,  G01N2333/52 ,  G01N2333/57

摘要： The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and SIV, or between HIV and FIV. In another embodiment, the epitope is one that is conserved between HIV, SIV, and FIV.

公开(公告)号：US09782472B2

公开(公告)日：2017-10-10

申请号：US13079472

申请日：2011-04-04

申请人： Phillip Berman ,  Sara O'Rourke ,  William Scott

发明人： Phillip Berman ,  Sara O'Rourke ,  William Scott

IPC分类号： C07K14/005 ,  A61K38/16 ,  C07K14/00 ,  C07H21/04 ,  C07K14/47 ,  A61K39/21 ,  G01N33/569 ,  A61K39/12

CPC分类号： A61K39/21 ,  A61K38/162 ,  A61K39/12 ,  C07K14/005 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12N2740/16134 ,  G01N33/56988 ,  G01N2333/162 ,  G01N2500/02

摘要： Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity.

公开(公告)号：US09777044B2

公开(公告)日：2017-10-03

申请号：US14575132

申请日：2014-12-18

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE DE MONTPELLIER 2

发明人： Jean-Luc Battini ,  Nicolas Manel ,  Felix Kim ,  Sandrina Kinet ,  Naomi Taylor ,  Marc Sitbon

IPC分类号： C07K14/005 ,  C12N7/00 ,  C07K14/62 ,  C07K14/705 ,  G01N33/566 ,  G01N33/574 ,  A61K38/00

CPC分类号： C07K14/005 ,  A61K38/00 ,  C07K14/62 ,  C07K14/705 ,  C12N2740/14022 ,  C12N2740/14033 ,  C12N2740/15022 ,  C12N2740/15045 ,  C12N2810/6054 ,  G01N33/566 ,  G01N33/57484 ,  G01N2333/62

摘要： The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.

公开(公告)号：US20160237123A1

公开(公告)日：2016-08-18

申请号：US15146511

申请日：2016-05-04

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

公开(公告)号：US20160152667A1

公开(公告)日：2016-06-02

申请号：US15019558

申请日：2016-02-09

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/10

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

摘要翻译： 本发明提供了利用在稳定的α-螺旋结构（本文中也称为SAH）中具有病毒α-螺旋七肽重复结构域的多肽的组合物，试剂盒和方法。 该组合物可用于治疗和/或预防病毒感染。 本发明至少部分地基于本文提供的结果，证明病毒性碳氢化合物钉扎的α螺旋肽显示优异的蛋白水解，酸和热稳定性，恢复肽的天然α-螺旋结构，在干扰 病毒融合过程，并且与相应的未修饰的肽相比具有优异的药代动力学性质。